A recent study indicates that people who come off new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who end conventional diet and exercise plans.
Published data in a prominent health publication points out that while obese people can lose about a fifth of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these treatments must be informed of the risk of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to original mass in about a year and a half.
Comparing Therapies
The study, which reviewed 37 of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that people who lose weight through lifestyle changes alone generally see a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Regain
Experts believe the mechanism of the drugs explains the accelerated rebound.
These medications mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
The NHS advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, due to the high risk of relapse, the therapy should be considered long-term.
This perspective is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," akin to managing diseases like diabetes.
User Accounts
Users who have discontinued the medication describe a sudden resurgence of cravings.
"I experienced a trigger flipping and you become extremely hungry," recalled one woman.
This challenge is exacerbated if users have not developed sustainable lifestyle or habit changes during treatment.
Significant Interest
Survey data indicate that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high.
- Adoption is higher among women than men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while these medications are powerful tools for shedding pounds, they are not a magic fix and lasting health benefits hinges on ongoing behavioural management.
